Nuvo Scores $2M Payment From Galderma For Launch Of Topical Anesthetic In Brazil

Following launches in the U.S. and European Union earlier this year, Nuvo Research and its licensing partner Galderma announced that Pliaglis, a topical local anesthetic, has been approved for sale and marketing in Brazil and is expected to launch in early 2014. Nuvo will receive a $2 million payment from Galderma for attaining this milestone.

Pliaglis uses Nuvo's phase-changing technology to form a pliable peel on the skin when exposed to air. According to the company, Pliaglis is indicated for use on intact skin in adults to provide local analgesia for superficial aesthetic procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal.

The original promotion and distribution agreement for Pliaglis was inked in 2008 between ZARS Pharma and Galderma. Nuvo acquired ZARS two years ago.

This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.